Loading...
Zealand Pharma A/S
ZLDPF•PNK
Healthcare
Biotechnology
$61.06
$2.66(4.55%)
Zealand Pharma A/S (ZLDPF) Financial Performance & Income Statement Overview
Review Zealand Pharma A/S’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-81.71%
↓ 81.71%
Operating Income Growth
-122.32%
↓ 122.32%
Net Income Growth
-53.30%
↓ 53.30%
Operating Cash Flow Growth
-118.67%
↓ 118.67%
Operating Margin
-2555.76%
↓ 2555.76%
Gross Margin
93.39%
↑ 93.39%
Net Profit Margin
-2128.64%
↓ 2128.64%
ROE
-13.47%
↓ 13.47%
ROIC
-16.24%
↓ 16.24%
Zealand Pharma A/S (ZLDPF) Income Statement & Financial Overview
Review Zealand Pharma A/S's (ZLDPF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $9.06M | $4.42M | $34.13M | $15.09M |
| Cost of Revenue | $408000.00 | -$6.62M | $9.49M | $11.21M |
| Gross Profit | $8.65M | $11.04M | $24.64M | $3.87M |
| Gross Profit Ratio | $0.95 | $2.50 | $0.72 | $0.26 |
| R&D Expenses | $253.92M | $263.50M | $211.52M | $190.94M |
| SG&A Expenses | -$20.81M | $93.81M | $80.80M | $68.78M |
| Operating Expenses | $407.93M | $360.45M | $292.32M | $259.71M |
| Total Costs & Expenses | $408.33M | $353.83M | $301.81M | $270.93M |
| Interest Income | $62.61M | $68.49M | $31.15M | $19.77M |
| Interest Expense | $11.21M | $8.79M | $57.54M | $4.80M |
| Depreciation & Amortization | $6.28M | $6.19M | $6.76M | $6.62M |
| EBITDA | -$274.12M | -$252.79M | -$260.92M | -$216.93M |
| EBITDA Ratio | -$30.27 | -$57.26 | -$7.64 | -$14.38 |
| Operating Income | -$399.28M | -$349.41M | -$267.68M | -$255.84M |
| Operating Income Ratio | -$44.09 | -$79.14 | -$7.84 | -$16.96 |
| Other Income/Expenses (Net) | $107.67M | $81.64M | -$26.39M | $25.84M |
| Income Before Tax | -$291.61M | -$267.77M | -$294.07M | -$230.00M |
| Income Before Tax Ratio | -$32.20 | -$60.65 | -$8.62 | -$15.24 |
| Income Tax Expense | -$574000.00 | -$1.38M | -$1.32M | -$1.35M |
| Net Income | -$291.03M | -$266.40M | -$292.75M | -$228.65M |
| Net Income Ratio | -$32.14 | -$60.34 | -$8.58 | -$15.15 |
| EPS | -$4.38 | -$3.77 | -$4.67 | -$3.71 |
| Diluted EPS | -$4.38 | -$3.77 | -$4.67 | -$3.71 |
| Weighted Avg Shares Outstanding | $70.65M | $70.66M | $62.69M | $61.63M |
| Weighted Avg Shares Outstanding (Diluted) | $70.65M | $70.66M | $62.69M | $61.63M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan